Ep. 5 - TrumpRx Expansion, FTC Pressure and the Growing Push for PBM Transparency
About this episode
Mike and Madison discuss the expansion of TrumpRx and the implications of FTC actions on PBMs.
Mike and Madison discuss TrumpRx's expansion to include more than 600 generic drugs, Optum Rx's latest pharmacy transparency announcement and what potential Federal Trade Commission action against PBMs could mean for plan sponsors. Register for upcoming Employers Health webinars or watch on demand at https://www.employershealthco.com/resource-center/events/ Sign up for our monthly newsletter at https://www.employershealthco.com/#subscribe_cta Find additional helpful benefits strategies and resources at https://www.employershealthco.com/resource-center/articles/
People in this episode
Hosts: Mike, Madison
Topics covered
- pharmacy benefits
- PBM transparency
- generic drugs
- FTC action
- healthcare management
Keywords
- TrumpRx
- Optum Rx
- PBM transparency
- generic drugs
- FTC
- pharmacy benefits
Mentioned in this episode
Organizations: TrumpRx, Optum Rx, Federal Trade Commission
More episodes of HR Benecast
- Ep. 6 - The CVS and FTC Settlement: What it Means for Plan Sponsors
- Episode 64 - How Bath & Body Works Approaches Open Enrollment for a Large Workforce
- Ep. 5 - Claim Adjudication and Reconciliation: Key Concepts Plan Sponsors Should Know
- Episode 63 - Zerigo Health and At-Home Phototherapy: Better Chronic Skin Condition Outcomes at a Lower Cost
- Episode 62 - A Conversation with the 2026 Employers Health Excellence in Benefits Award Winner
- Episode 61 - GLP-1s, Biosimilars and Pharmacy Spend: Insights from Employers Health's Book of Business
Explore listener stats, chart rankings, contacts and more on the HR Benecast podcast page.